The Current Status of Allogenic Islet Cell Transplantation
Type 1 Diabetes (T1D) is an autoimmune destruction of pancreatic beta cells. The development of the Edmonton Protocol for islet transplantation in 2000 revolutionized T1D treatment and offered a glimpse at a cure for the disease. In 2022, the 20-year follow-up findings of islet cell transplantation...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/20/2423 |
| _version_ | 1797574320584654848 |
|---|---|
| author | Zofia Czarnecka Nidheesh Dadheech Haide Razavy Rena Pawlick A. M. James Shapiro |
| author_facet | Zofia Czarnecka Nidheesh Dadheech Haide Razavy Rena Pawlick A. M. James Shapiro |
| author_sort | Zofia Czarnecka |
| collection | DOAJ |
| description | Type 1 Diabetes (T1D) is an autoimmune destruction of pancreatic beta cells. The development of the Edmonton Protocol for islet transplantation in 2000 revolutionized T1D treatment and offered a glimpse at a cure for the disease. In 2022, the 20-year follow-up findings of islet cell transplantation demonstrated the long-term safety of islet cell transplantation despite chronic immunosuppression. The Edmonton Protocol, however, remains limited by two obstacles: scarce organ donor availability and risks associated with chronic immunosuppression. To overcome these challenges, the search has begun for an alternative cell source. In 2006, pluripotency genomic factors, coined “Yamanaka Factors,” were discovered, which reprogram mature somatic cells back to their embryonic, pluripotent form (iPSC). iPSCs can then be differentiated into specialized cell types, including islet cells. This discovery has opened a gateway to a personalized medicine approach to treating diabetes, circumventing the issues of donor supply and immunosuppression. In this review, we present a brief history of allogenic islet cell transplantation from the early days of pancreatic remnant transplantation to present work on encapsulating stem cell-derived cells. We review data on long-term outcomes and the ongoing challenges of allogenic islet cell and stem cell-derived islet cell transplant. |
| first_indexed | 2024-03-10T21:21:21Z |
| format | Article |
| id | doaj.art-245deda7422d4ca2875ced66c9ebb538 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T21:21:21Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-245deda7422d4ca2875ced66c9ebb5382023-11-19T16:01:55ZengMDPI AGCells2073-44092023-10-011220242310.3390/cells12202423The Current Status of Allogenic Islet Cell TransplantationZofia Czarnecka0Nidheesh Dadheech1Haide Razavy2Rena Pawlick3A. M. James Shapiro4Department of Surgery, University of Alberta, Edmonton, AB T6G 2RW3, CanadaDepartment of Surgery, University of Alberta, Edmonton, AB T6G 2RW3, CanadaDepartment of Surgery, University of Alberta, Edmonton, AB T6G 2RW3, CanadaDepartment of Surgery, University of Alberta, Edmonton, AB T6G 2RW3, CanadaDepartment of Surgery, University of Alberta, Edmonton, AB T6G 2RW3, CanadaType 1 Diabetes (T1D) is an autoimmune destruction of pancreatic beta cells. The development of the Edmonton Protocol for islet transplantation in 2000 revolutionized T1D treatment and offered a glimpse at a cure for the disease. In 2022, the 20-year follow-up findings of islet cell transplantation demonstrated the long-term safety of islet cell transplantation despite chronic immunosuppression. The Edmonton Protocol, however, remains limited by two obstacles: scarce organ donor availability and risks associated with chronic immunosuppression. To overcome these challenges, the search has begun for an alternative cell source. In 2006, pluripotency genomic factors, coined “Yamanaka Factors,” were discovered, which reprogram mature somatic cells back to their embryonic, pluripotent form (iPSC). iPSCs can then be differentiated into specialized cell types, including islet cells. This discovery has opened a gateway to a personalized medicine approach to treating diabetes, circumventing the issues of donor supply and immunosuppression. In this review, we present a brief history of allogenic islet cell transplantation from the early days of pancreatic remnant transplantation to present work on encapsulating stem cell-derived cells. We review data on long-term outcomes and the ongoing challenges of allogenic islet cell and stem cell-derived islet cell transplant.https://www.mdpi.com/2073-4409/12/20/2423type 1 diabetesisletallogenictransplantationstem cellimmunosuppression |
| spellingShingle | Zofia Czarnecka Nidheesh Dadheech Haide Razavy Rena Pawlick A. M. James Shapiro The Current Status of Allogenic Islet Cell Transplantation Cells type 1 diabetes islet allogenic transplantation stem cell immunosuppression |
| title | The Current Status of Allogenic Islet Cell Transplantation |
| title_full | The Current Status of Allogenic Islet Cell Transplantation |
| title_fullStr | The Current Status of Allogenic Islet Cell Transplantation |
| title_full_unstemmed | The Current Status of Allogenic Islet Cell Transplantation |
| title_short | The Current Status of Allogenic Islet Cell Transplantation |
| title_sort | current status of allogenic islet cell transplantation |
| topic | type 1 diabetes islet allogenic transplantation stem cell immunosuppression |
| url | https://www.mdpi.com/2073-4409/12/20/2423 |
| work_keys_str_mv | AT zofiaczarnecka thecurrentstatusofallogenicisletcelltransplantation AT nidheeshdadheech thecurrentstatusofallogenicisletcelltransplantation AT haiderazavy thecurrentstatusofallogenicisletcelltransplantation AT renapawlick thecurrentstatusofallogenicisletcelltransplantation AT amjamesshapiro thecurrentstatusofallogenicisletcelltransplantation AT zofiaczarnecka currentstatusofallogenicisletcelltransplantation AT nidheeshdadheech currentstatusofallogenicisletcelltransplantation AT haiderazavy currentstatusofallogenicisletcelltransplantation AT renapawlick currentstatusofallogenicisletcelltransplantation AT amjamesshapiro currentstatusofallogenicisletcelltransplantation |